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Abstract
In some high-risk patients, standard mitral valve replacement can represent a challenging procedure, requiring a risky extensive decalciﬁ-
cation of the annulus. In particular, high-risk redo patients and patients with a previously implanted transcatheter aortic valve, who
develop calciﬁc mitral disease, would beneﬁt from the development of new, minimally invasive, transcatheter or hybrid techniques for
mitral valve replacement. In particular, mixing transcatheter valve therapies and well-established minimally invasive techniques for mitral
replacement or repair can help in decreasing the surgical risk and the technical complexity. Thus, placing transcatheter, balloon-
expandable Sapien™ XT stent-valves in calciﬁed, degenerated mitral valves through a right thoracotomy, a left atriotomy and on an
on-pump ﬁbrillating heart, represents an attractive alternative to standard surgery in redo patients, in patients with concomitant transcath-
eter aortic stent-valves in place and in patients with a high-risk proﬁle. We describe this hybrid technique in detail.
Keywords: Transcatheter valve replacement • Mitral valve stenosis • Mitral valve replacement • High-risk patients
INTRODUCTION
Mitral valve replacement with biological prosthesis is a valid treat-
ment for elderly patients with non-repairable mitral disease [1–3].
However, mitral stenosis sometimes represents a challenging pro-
cedure, requiring valve replacement and extensive decalciﬁcation
of the annulus, with risk of ventricular damage and bleeding [4].
Thus, new, minimally invasive, transcatheter or hybrid techniques
for mitral replacement could represent a further step in the treat-
ment of selected high-risk patients.
Moreover, in recent years, high-risk patients with aortic stenosis
have, worldwide, undergone the transcatheter implantation of
aortic stent-valves and those developing a concomitant mitral
disease will also take advantage of the development of new
hybrid techniques [5]. The placement of the balloon-expandable
Sapien™ XT (Edwards Lifesciences, Irvine, CA, USA) stent-valve
in calciﬁed mitral valves through a right thoracotomy, a left
atriotomy and on an on-pump ﬁbrillating heart represents an
attractive new alternative to standard surgery in redo patients,
patients with concomitant aortic stent-valves and patients with
high-risk proﬁle.
PROCEDURAL DETAILS
To explain the technique, an actual case is described as follows.
A 60-year-old man with symptomatic mitral stenosis was
screened for minimally invasive surgery at our institution. His
clinical history showed rheumatic fever, previous mediastinal
radiotherapy for lymphoma, chronic renal insufﬁciency and
chronic obstructive pulmonary disease. Due to concomitant
thorax irradiation and rheumatic fever, the patient also devel-
oped a severe symptomatic aortic stenosis: the screening, per-
formed in 2010 in another European country, showed a
‘porcelain’ aorta and the presence of rare blood antibodies limit-
ing transfusions in case of haemorrhage (GERBICH-positive). The
standard aortic valve replacement was considered to be high-risk
and the patient was successfully treated, in that centre, with a 26
mm CoreValve® (Medtronic, Minneapolis, MN, USA). After
having considered the comorbidities and the limiting factors
(porcelain aorta and antibodies) we identiﬁed in the on-pump
ﬁbrillating heart through a right thoracotomy, the best way to
approach the mitral valve. However, the presence of the
CoreValve® and heavy mitral calciﬁcations precluded some
therapeutic options and the deployment of a balloon-
expandable Sapien™ XT under direct view was considered the
best option to reduce the cardiopulmonary bypass time, the risk
of haemorrhage after extensive decalciﬁcation and the risk of
CoreValve® displacement during manipulations. The pre-operative
transoesophageal echocardiogram (TEE) showed a calciﬁed mitral
valve with gradients of 29 mmHg and 17 mmHg (Fig. 1A and B), a
well-functioning CoreValve®, pulmonary hypertension (mean pres-
sure: 45 mmHg), a dilated left atrium and good left function. The cor-
onary angiogram showed absence of coronary disease. The patient
accepted a non-conventional approach and signed the consent.
EuroSCOREs 1 (logistic) and 2 were 23 and 8%, respectively.
© The Author 2013. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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The procedure was performed in the operating theatre with TEE
and ﬂuoroscopic monitoring: after the femoro-femoral cannulation
and the right thoracotomy at fourth intercostal space, a left vent
was placed in the right superior pulmonary vein and the ﬁbrillator
was switched on once on full bypass. The left atrium was opened
(CO2 use) and the mitral valve exposed; this conﬁrmed the diagno-
sis and the risk of performing extensive decalciﬁcations. Following
our strategy, we prepared a 29 mm Sapien™ XT valve while three
3-0 polypropylene U-stitches with pledgets were placed at commis-
sures and at posterior leaﬂet midpoint to ﬁx the deployed valve
(Fig. 1C). Then, the mitral valvuloplasty was performed (Fig. 1F) and
the Sapien™ was placed across the mitral valve under direct and
ﬂuoroscopic view: half a centimetre of the bared stent was left in
the atrium, where pre-placed U-stitches would be ﬁxed, in order to
prevent paravalvular leaks (Fig. 1D–G). After that, the Sapien™ was
deployed (Fig. 1H) and ﬁxed to the annulus using the three stitches
(Fig. 1E–I). The left atrium was closed with the vent in place, the
ﬁbrillator was switched off and the cardiopulmonary bypass was
weaned (ﬁbrillating time: 20 min; cardiopulmonary bypass time:
26 min). Judging by our experience, the patient recovery was good,
with rapid extubation and absence of paravalvular leak. The post-
operative chest radiogram and echocardiogram revealed absence
of interference between the two valves and an invasive aortic meas-
urement showed a trans valvular peak gradient of less than 10
mmHg (Fig. 2).
CONCLUSION
Standard mitral replacement can be difﬁcult in the presence of
heavy calciﬁcations and can lead to severe complications.
Additionally, the concomitant presence of previously implanted
transcatheter aortic valves (in particular the self-expandable
stent-valves) can limit the access site, the decalciﬁcation and the
placement of a standard prosthesis [1–5]. In this scenario, hybrid
techniques may help in ﬁnding safer, faster and easier way to
treat complex valve diseases. In particular, the use of the
balloon-expandable Sapien™ valve in a calciﬁed mitral valve
appears easy, useful, and does not seem to interfere with
the ventricular outﬂow tract and the left atrium because of its
Figure 1: (A, B) show a 3-dimensional echocardiogram of a stenotic mitral valve in systole and diastole. (C–E) are intra-operative views showing: (C) the calciﬁed mitral
valve with three 3-0 polypropylene U-stitches placed at the commissures and at the posterior leaﬂet midpoint (white arrows), (D) introduction of the delivery system
with the crimped valve across the diseased mitral valve and (E) the deployed stent valve in mitral position with the three stay sutures assuring the anchorage. F–I are
ﬂuoroscopic views showing: (F) mitral balloon valvuloplasty, (G) stent-valve placement and ballooning, (H) full inﬂation and (I) ﬁnal result with the Sapien™ XT in
mitral position and the CoreValve® in aortic position.
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low-proﬁle design. In our limited experience, the short delivery
system was easy to manipulate through the thoracotomy, did not
require the Ascendra™ sheat, and the Sapien™ was easily placed
and deployed under direct and ﬂuoroscopic view (to control
interference with the stent-valve in the aortic position). We used
three stitches to secure the valve at the annulus but it is likely
that the Sapien™ can remain in place without surgical ﬁxation
(more laboratory tests are required before proceeding with
transapical or direct transatrial off-pump procedures). This
hybrid technique is useful in tricky and redo cases and the fact
that the Sapien™ could remain in place without direct ﬁxation
may pave the way for future transcatheter off-pump mitral repla-
cements via a mini-thoracotomy or thoracoscopy, as already
proposed for valve-in-valve procedures in cases of a degener-
ated bioprosthesis [6–8].
In conclusion, we should remember that rheumatic fever is still
the main cause of mitral stenosis in several eastern, middle-
eastern and developing countries, and a hybrid on-pump ﬁbrillating
heart approach may represent an excellent alternative to standard
surgery in high-risk patients.
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Figure 2: Postoperative imaging showing: (A and B) the thorax radiograms, (C) the transthoracic echocardiogram with the Sapien™ XT (red arrow) and the CoreValve®
(green arrow) and (D) the invasive intracardiac left pressures showing a low trans-aortic gradient.
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